EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions to Participate in Investor Conferences

GAITHERSBURG, Md., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences in the first quarter of 2021:

  • 39th Annual J.P. Morgan Healthcare Conference

    January 11 to 14, 2021

    Company presentation scheduled on January 11 at 8:20am EST



  • J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference

    March 1 to 3, 2021

    Presentation date and time will be updated on the Emergent website as the information becomes available.



  • Cowen 41st Annual Health Care Conference

    March 1 to 4, 2021

    Presentation date and time will be updated on the Emergent website as the information becomes available.

For conferences where a presentation is planned, the company’s webcast presentation may include a discussion of the company's recent business developments as well as its financial results and guidance. The webcasts will be available both live, if possible, and by replay, and will be accessible from the .

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information, visit our and follow us on , , and .

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

  

Media Contact:

Miko B. Neri

Senior Director, Global Communications & Public Affairs

240-631-3392



EN
04/01/2021

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Emergent BioSolutions Reports Third Quarter 2025 Financial Results Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 millionThird Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200 bps, respectively, versus prior yearThird Quarter 2025 Adjusted EBITDA of $87.8 million and Adjusted EBITDA Margin of 38%Raising the Full Year 2025 Revenue and Profitability GuidanceStrong Sequential Naloxone Revenue Growth, Primarily Driven b...

October 29, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Releases New Survey Findings Revealing Heightene...

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting concerns around bioterrorism and the nation’s readiness to respond GAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new survey1 of approximately 250 U.S. policy opinion leaders showing that nearly two-thirds (65 percent) of respondents agree the likelihood of ...

October 28, 2025 1 EN
Free Trial
EBS Emergent BioSol...

Emergent Biosolutions Inc: 1 director

A director at Emergent Biosolutions Inc sold 30,608 shares at 10.000USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

EBS EMERGENT BIOSOLUTIONS INC.
10/16/25 October 16, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Report Third Quarter 2025 Financial Results o...

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 GAITHERSBURG, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, October 29, 2025, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2025. Participants can access the conference call live via and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing ...

October 8, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Recognizes Several Important Observances to Help...

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc. (NYSE: EBS) today recommitted to its leadership combating the opioid crisis through a multi-faceted approach focused on awareness, education and widespread access to naloxone, including NARCAN® Nasal Spray 4 mg and KLOXXADO® (naloxone...

September 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch